Novo Nordisk has accused Singapore-based biotech KBP Biosciences of concealing clinical data ahead of a $1.3 billion licensing agreement between the two companies in 2023 focused on blood pressure ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...